Abstract:To explore the material basis and mechanism of Chinese compound Zhibai Dihuang Pill in the treatment of metabolic syndrome by the application of network pharmacology research methods.Methods:Through the Chinese Medicine System Pharmacology Technology Platform (TCMSP) database,the main active components of traditional Chinese medicine compound Rhizoma Anemarrhenae,Cortex Phellodendri,Radix Rehmanniae Preparata,Fructus Corni,Rhizoma Dioscoreae,Cortex Moutan Radicis,Rhizoma Alismatis were retrieved and made for target prediction.The OMIM,TTD,and DisGeNET databases were used to retrieve the relevant disease targets of the metabolic syndrome,and the eight-flavored Chinese medicine target was intersected with the disease target to screen for a common target.The STRING platform was used to construct a protein-protein interaction(PPI) network model,and the network was topologically analyzed by using Cytoscape software to obtain the core target.GO-BP biofunctional enrichment analysis and KEGG pathway analysis were performed on the core targets by Metascape software.Results:By database analysis,it was inferred that the database of Chinese medicine compound Zhibai Dihuang Pill contained 74 active compounds,906 target sites,and 290 targets shared with metabolic syndrome.Through the topological analysis of common targets,the core of Chinese medicine compound Zhibai Dihuang Pill was screened for 78 target.From GO-BP biological function enrichment and KEGG pathway analysis,it was found that through the circulatory system,G protein coupled receptor signaling pathway,lipopolysaccharide regulation,regulation of blood pressure,lipid metabolism regulation and other biological functions,and a variety of metabolic pathways such as calcium signaling pathway,VEGF signaling pathway and ErbB signaling pathway they played a therapeutic role.Conclusion:This study explored the material basis and mechanism of Chinese medicine compound Zhibai Dihuang Pill in the treatment of metabolic syndrome,and provided a new scientific basis for its clinical and basic research.